Bepotastine/montelukast - Hyundai Pharmaceutical
Alternative Names: HDDO-1801; HDDO-18011/HDDO-18012Latest Information Update: 28 Oct 2024
At a glance
- Originator Hyundai Pharmaceutical
- Class Acetates; Anti-inflammatories; Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Bronchodilators; Chlorobenzenes; Piperidines; Pyridines; Quinolines
- Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Respiratory-tract-disorders in South Korea (PO)
- 01 Sep 2021 Phase-I clinical trials in Respiratory tract disorders in South Korea (PO) (Hyundai Pharmaceutical pipeline, September 2021)
- 06 Apr 2020 Bepotastine/montelukast - Hyundai Pharmaceutical is available for licensing as of 06 Apr 2020. http://www.hyundaipharm.co.kr/